0.2203

2.69% -0.0061

After Hours: .22 -0.0003 -0.14%

Scisparc Ltd (SPRC)

Overview News Price History Why SPRC Down? Discussions Forecast Stock Split

Scisparc Ltd stock is traded at $0.2203, with a volume of 439.74K. It is down -2.69% in the last 24 hours and down -3.38% over the past month. SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.

Previous Close:

$0.2264

Open:

$0.221

24h Volume:

439.74K

Relative Volume:

0.46

Market Cap:

$2.28M

Revenue:

$2.88M

Net Income/Loss:

$-5.12M

P/E Ratio:

-0.000816

EPS:

-269.9888

Net Cash Flow:

1W Performance:

-7.48%

1M Performance:

-3.38%

6M Performance:

-80.50%

1Y Performance:

-97.86%

1-Day Range:

$0.2083

$0.2298

1-Week Range:

$0.2083

$0.29

52-Week Range:

$0.2055

$10.45

Scisparc Ltd Stock (SPRC) Company Profile

Name

Scisparc Ltd

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

Address

Employee

Twitter

Next Earnings Date

Latest SEC Filings

SPRC's Discussions on Twitter

Compare SPRC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SPRC Scisparc Ltd	0.2203	2.28M	2.88M	-5.12M	0	-269.99
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Scisparc Ltd Stock (SPRC) Latest News

Nov 23, 2024

SciSparc Ltd. Enters into Letter of Intent with Jeffs' Brands Ltd - Marketscreener.com

Nov 23, 2024

Nov 04, 2024

SciSparc Ltd. Reports Changes in Financial Position - TipRanks

Nov 04, 2024

SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com

Nov 04, 2024

Oct 23, 2024

Financial Metrics Unveiled: SciSparc Ltd (SPRC)’s Key Ratios in the Spotlight - The Dwinnex

Oct 16, 2024

Oct 09, 2024

SPRC Stock Hits 52-Week Low at $0.21 Amid Market Challenges - Investing.com

Oct 09, 2024

Oct 08, 2024

SciSparc gains as Clearmind partnership yields 3 new international patent applications - MSN

Oct 08, 2024

Oct 01, 2024

SciSparc stock plunges to 52-week low, hits $0.23 - Investing.com India

Oct 01, 2024

Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome - 420 Intel

Oct 01, 2024

SciSparc receives FDA approval for trial for Tourette syndrome therapy - Clinical Trials Arena

Oct 01, 2024

SciSparc gets U.S. FDA nod to begin phase 2 trial of Tourette Syndrome candidate - MSN

Oct 01, 2024

Sep 30, 2024

FDA greenlights SciSparc's Phase IIb Tourette Syndrome study By Investing.com - Investing.com South Africa

Sep 30, 2024

Pharmaceutical FDA Next Phase Cannabinoid For TouretteSciSparc (NASDAQ:SPRC) - Benzinga

Sep 30, 2024

SciSparc secures FDA approval to launch Phase IIB trial for TS treatment - TipRanks

Sep 30, 2024

FDA greenlights SciSparc's Phase IIb Tourette Syndrome study - Investing.com

Sep 30, 2024

SciSparc Secures FDA Green Light to US Launch of its - GlobeNewswire

Sep 30, 2024

Financial Metrics Check: SciSparc Ltd (SPRC)’s Ratios for Trailing Twelve Months - The Dwinnex

Sep 30, 2024

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment - StockTitan

Sep 30, 2024